Acceleron promised they had great data on sotatercept in late January. But was it good enough to justify a doubling of the stock price?
The stock price of Acceleron $XLRN has almost doubled since the biotech announced in late January that its mid-stage study of sotatercept cleared the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
